FDA Expands EUA for Pfizer/BioNTech COVID-19 Booster to Children 5 to 11 Years

May 17th 2022

The booster is given at least five months after completion of a primary series.

FDA Clears First At-Home Combo COVID-19, RSV and Flu Test

May 17th 2022

The FDA emergency use authorization allows the nonprescription test to use at-home sample collection with testing performed in a laboratory.

FDA Declines EUA for Fluvoxamine for COVID-19

May 17th 2022

FDA regulators said the data to support the EUA, which was submitted by a physician, is not sufficient to support the use of the antidepressant fluvoxamine for the treatment of patients with COVID-19.

Demand for Real-World Evidence of Medications is Growing

May 16th 2022

The role of health economic and real-world evidence has become, and will continue to be, an important aspect of healthcare decision-making.

FDA Okays Lilly’s Novel Diabetes Drug

May 16th 2022

Mounjaro is a first-in-class medicine that activates both the GLP-1 and GIP receptors, which leads to improved blood sugar control.